News
Public · Published
Amgen Price Target Raised to $536.00/Share From $481.00 by Goldman Sachs
Goldman Sachs raised its price target for Amgen to $536.00 per share from $481.00. The firm maintained its Buy rating on the company, according to the supplied ratings-action text.
Published:
Updated:
What happened
Goldman Sachs raised its price target for Amgen to $536.00 per share from $481.00. The firm maintained its Buy rating on the company, according to the supplied ratings-action text.
Confirmed
Global impact / market context
A higher price target signals that Goldman Sachs sees more potential value in Amgen shares than before, while keeping its Buy rating. If investors act on that view, demand for the shares could rise, though the article gives no forecast details or evidence of a market reaction.
Analyst inference
The item reports only an analyst opinion change: a higher target alongside an unchanged Buy rating. It provides no explanation of the valuation, no company operating updates, and no share-price response, so it does not establish a change in Amgen’s business outlook.
Confirmed
What to watch
- Look for Goldman Sachs’s reasoning behind the higher target, including any stated assumptions about Amgen’s revenue, costs, or future cash available to fund operations. Analyst inference
- Check whether Amgen releases business updates that support or challenge the analyst’s more optimistic share-value estimate; none are included in this supplied item. Analyst inference
- Watch for subsequent analyst rating or target changes, which could indicate whether Goldman Sachs’s more positive view is being shared or revised by other firms. Analyst inference
Evidence
- Original source link unavailable